Diagnostic value of FDG-PET in recurrent colorectal carcinoma: A meta-analysis

International Journal of Cancer

Volumn 124, Issue 1, 2009, Pages 167-173

  Zhang, Chenpeng ^a   Chen, Yumei ^a   Xue, Huiping ^a   Zheng, Ping ^b   Tong, Jinlu ^a   Liu, Jianjun ^a   Sun, Xiaoguang ^a   Huang, Gang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Sixth People's Hospital   (China)

Author keywords

Colorectal; Emission computed; Meta analysis; Recurrence; Tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; HUMAN; LIVER METASTASIS; META ANALYSIS; PELVIS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ADULT; AGED; CARCINOMA; COLORECTAL TUMOR; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; ROC CURVE; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECURRENCE; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 58149383085     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23926     Document Type: Article

References (46)

1. Desch CE, Benson AB, III, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Pfister DG, Virgo KS, Petrelli NJ. Colorectal cancer surveillance: 2005 update of an American society of clinical oncology practice guideline. J Clin Oncol 2005;23:8512-19.
2. Pommier R, Woltering EA. Follow-up of patients after primary colorectal cancer resection. Semin Surg Oncol 1991;7:129-32.
3. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, Gambhir SS. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41:1177-89.
4. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninva- sive imaging methods (US. CT, MR imaging. PET): a meta-analysis. Radiology 2002;224:748-56.
5. Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwin- derman AH, Stoker J. Colorectal liver metastases: CT MR imaging, and PET for diagnosis-meta-analysis. Radiology 2005;237:123-31.
6. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005;15:2658-70.
7. Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, Marchal G, Filez L, Aerts R. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517-22.
8. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birn-baum EH, Fleshman JW, Read TE, Philpott GW, Kodner IJ. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613-20.
9. Keogan MT, Lowe VJ, Baker ME, McDermott VG, Lyerly HK, Coleman RE. Local recurrence of rectal cancer: evaluation with F- 18 fluorodeoxyglucose PET imaging. Abdom Imaging 1997;22:332-37.
10. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227:319-23.
11. Valk PE, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myers RW, Greiss HB, Hofer GA. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503-11.
12. Staib L, Schirrmeister H, Reske SN, Beger HG. Is (18)F-fluorodeoxy- glucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg 2000;180:1-5.
13. Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, Birnbaum EH, Fleshman JW, Kodner IJ, Read TE. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000;43:759-67.
14. Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroo- bants S, Peeters M, Penninckx F, Filez L, Bleichrodt RP, Mortelmans L. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 2001;37:862-69.
15. Hung GU, Shiau YC, Tsai SC, Chao TH, Ho YJ, Kao CH. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res 2001;21:1375-78.
16. Arulampalam T, Costa D, Visvikis D, Boulos P, Taylor I, Ell P. The impact of FDG-PET on the management algorithm for recurrent col- orectal cancer. Eur J Nucl Med 2001;28:1758-65.
17. Libutti SK, Alexander HR, Jr, Choyke P, Bartlett DL, Bacharach SL, Whatley M, Jousse F, Eckelman WC, Kranda K, Neumann RD, Carrasquillo JA. A prospective study of 2-[18F] fluoro-2-deoxy-D- glucose/positron emission tomography scan, 99mTc-labeled arcitu- momab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol 2001;8:779-86.
18. Johnson K, Bakhsh A, Young D, Martin TE, Jr, Arnold M. Correlating computed tomography and positron emission tomography scan with operative findings in metastatic colorectal cancer. Dis Colon Rectum 2001;44:354-57.
19. Lonneux M, Reffad AM, Detry R, Kartheuser A, Gigot JF, Pauwels S. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2002;29:915-21.
20. Liu FY, Chen JS, Changchien CR, Yeh CY, Liu SH, Ho KC, Yen TC. Utility of 2-fluoro-2-deoxy-d-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcino- embryonic antigen elevation at different levels. Dis Colon Rectum 2005;48:1900-12.
21. Kim JH, Czernin J, Allen-Auerbach MS, Halpern BS, Fueger BJ, Hecht JR, Ratib O, Phelps ME, Weber WA. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 2005;46:587-95.
22. Nakamoto Y, Sakamoto S, Okada T, Senda M, Higashi T, Saga T, Togashi K. Clinical value of manual fusion of PET and CT images in patients with suspected recurrent colorectal cancer. AJR Am J Roent- genol 2007;188:257-67.
23. Beets G, Penninckx F, Schiepers C, Filez L, Mortelmans L, Kerre- mans R, Aerts R, De Roo M. Clinical value of whole-body positron emission tomography with [18F] fluorodeoxyglucose in recurrent colorectal cancer. Br JSurg 1994;81:1666-70.
24. Montravers F, Grahek D, Kerrou K, Younsi N, Petegnief Y, de Beco V, Colombet-Lamau C, Talbot JN. Detection of recurrent colorectal carcinoma by 18F-FDG: comparison of the clinical performances of FDG PET and FDG CDET. Nucl Med Commun 2004;25:105-13.
25. Willkomm P, Bender H, Bangard M, Decker P, Grüpnwald F, Biersack HJ. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma. J Nucl Med 2000;41:1657-663.
26. Selvaggi F, Cuocolo A, Sciaudone G, Maurea S, Giuliani A, Mainolfi C. FGD-PET in the follow-up of recurrent colorectal cancer. Colorec- tal Dis 2003;5:496-500.
27. Ruhlmann J, Schomburg A, Bender H, Oehr P, Robertz-Vaupel GM, Vaupel H, Wolter H, Kozak B, Biersack HJ. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 1997;40: 1195-204.
28. Vitola JV, Delbeke D, Sandler MP, Campbell MG, Powers TA, Wright JK, Chapman WC, Pinson CW. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21-26.
29. Delbeke D, Vitola JV, Sandler MP, Arildsen RC, Powers TA, Wright JK, Jr, Chapman WC, Pinson CW. Staging recurrent metastatic color- ectal carcinoma with PET. J Nucl Med 1997;38:1196-201.
30. Tanaka T, Kawai Y, Kanai M, Taki Y, Nakamoto Y, Takabayashi A. Usefulness of FDG-positron emission tomography in diagnosing peritoneal recurrence of colorectal cancer. Am J Surg 2002;184:433-36.
31. Imdahl A, Reinhardt MJ, Nitzsche EU, Mix M, Dingeldey A, Einert
32. A, Baier P, Farthmann EH. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg 2000;385:129-34.
33. Fukunaga H, Sekimoto M, Ikeda M, Higuchi I, Yasui M, Seshimo I, Takayama O, Yamamoto H, Ohue M, Tatsumi M, Hatazawa J, Ikenaga M, et al. Fusion image of positron emission tomography and computed tomography for the diagnosis of local recurrence of rectal cancer. Ann Surg Oncol 2005;12:561-69.
34. Lai DT, Fulham M, Stephen MS, Chu KM, Solomon M, Thompson JF, Sheldon DM, Storey DW. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996; 131:703-07.
35. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988;7:889-94.
36. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240:1027-34.
37. Even-Sapir E, Parag Y, Lerman H, Gutman M, Levine C, Rabau M, Figer A, Metser U. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 2004;232:815-22.
38. Bellomi M, Rizzo S, Travaini LL, Bazzi L, Trifirò G, Zampino MG, Radice D, Paganelli G. Role of multidetector CT and FDG-PET/CT in the diagnosis of local and distant recurrence of resected rectal cancer. Radiol Med (Torino) 2007;112:681-90.
39. Votrubova J, Belohlavek O, Jaruskova M, Oliverius M, Lohynska R, Trskova K, Sedlackova E, Lipska L, Stahalova V. The role of FDG- PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2006;33:779-84.
40. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77.
41. Yu C-H. Meta-analysis of diagnostic experiment (Excepted from FANG Ji-qian, chief-editor). Modern medical statistics. Beijing: People's Medical Publishing House, 2002.182-195.
42. Gu P, Huang G, Chen Y, Zhu C, Yuan J, Sheng S. Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis. J Clin Lab Anal 2007;21:398-405.
43. Liu T, Xu W, Yan WL, Ye M, Bai YR, Huang G. FDG-PET CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiother Oncol 2007; 85:327-35.
44. Lejeune C, Bismuth MJ, Conroy T, Zanni C, Bey P, Bedenne L, Fai- vre J, Arveux P, Guillemin F. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. J Nucl Med 2005;46:2020-28.
45. Park KC, Schwimmer J, Shepherd JE, Phelps ME, Czernin JR, Schiepers C, Gambhir SS. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg 2001;233:310-19.
46. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004;240:438-50.